文献速递重症综合管理与镇静镇痛

右美托咪定预防和治疗术后及重症监护病房谵妄:系统评价与荟萃分析

Dexmedetomidine in prevention and treatment of postoperative and intensive care unit delirium: a systematic review and meta-analysis.
PubMed 文献 · Ann Intensive Care · 2018-09-20
一句话结论右美托咪定可降低ICU谵妄发生率(RR 0.52–0.63),但增加心动过缓和低血压风险;治疗谵妄证据有限。

该系统评价与荟萃分析检索PubMed和Cochrane对照试验中心注册库(截至2018年8月1日),纳入成年ICU患者接受右美托咪定的随机对照试验。共28篇文章:25篇/4975例患者用于发生率比较,3篇/166例患者用于治疗比较。发生率比较中,右美托咪定较安慰剂(RR 0.52;95%CI 0.39-0.70;I²=37%)、标准镇静药(RR 0.63;95%CI 0.46-0.86;I²=69%)及阿片类(RR 0.61;95%CI 0.44-0.83;I²=0%)均显著降低谵妄总体发生率,但显著增加心动过缓和低血压风险。治疗比较中3项RCT对照药物分别为安慰剂、咪达唑仑和氟哌啶醇,谵妄缓解测量方法各异,2/3研究显示右美托咪定明确有利,与氟哌啶醇比较的试点研究(n=20)结果变异大。结论提示右美托咪定降低ICU谵妄发生率和持续时间,但治疗谵妄证据有限。

要点

  • 与安慰剂相比,右美托咪定显著降低ICU谵妄总体发生率(RR 0.52;95%CI 0.39-0.70;I²=37%)。
  • 与标准镇静药相比,右美托咪定显著降低谵妄发生率(RR 0.63;95%CI 0.46-0.86;I²=69%)。
  • 与阿片类相比,右美托咪定显著降低谵妄发生率(RR 0.61;95%CI 0.44-0.83;I²=0%)。
  • 使用右美托咪定显著增加心动过缓和低血压风险。
  • 治疗谵妄的证据有限:3项RCT中2项(对照安慰剂和咪达唑仑)显示明确有利,与氟哌啶醇比较的试点研究(n=20)结果变异大。

适用人群与场景

  • 成年ICU患者,接受右美托咪定与镇静药比较,评估ICU谵妄发生率或谵妄治疗。

研究设计与关键结果

  • 系统评价与荟萃分析,检索PubMed和Cochrane对照试验中心注册库(2018年8月1日),纳入成年ICU患者接受右美托咪定的随机对照试验。
  • 共纳入28篇文章:25篇/4975例患者用于发生率比较,3篇/166例患者用于治疗比较。
  • 发生率比较:右美托咪定较安慰剂显著降低谵妄总体发生率(RR 0.52;95%CI 0.39-0.70;I²=37%)。
  • 发生率比较:右美托咪定较标准镇静药显著降低谵妄发生率(RR 0.63;95%CI 0.46-0.86;I²=69%)。
  • 发生率比较:右美托咪定较阿片类显著降低谵妄发生率(RR 0.61;95%CI 0.44-0.83;I²=0%)。
  • 右美托咪定显著增加心动过缓和低血压风险;循环功能不全和死亡率数据有限。
  • 治疗比较:3项RCT对照药物分别为安慰剂、咪达唑仑和氟哌啶醇,谵妄缓解测量方法各异;2/3研究显示右美托咪定明确有利(对照安慰剂和咪达唑仑);与氟哌啶醇比较的试点研究(n=20)结果变异大。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入随机对照试验;采用Cochrane标准评估偏倚风险。
  • 不同亚组存在异质性(安慰剂组I²=37%,标准镇静药组I²=69%,阿片类组I²=0%)。
  • 循环功能不全和死亡率数据有限。
  • 与氟哌啶醇比较的试点研究(n=20)结果变异大。
  • 治疗谵妄的证据有限。

对床旁实践的改变

  • 作者认为,右美托咪定降低ICU谵妄发生率和持续时间。
  • 系统检索显示,关于是否应使用右美托咪定治疗谵妄的证据有限。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To determine the preventive and therapeutic effect of dexmedetomidine on intensive care unit (ICU) delirium.

METHODS: The literature search using PubMed and the Cochrane Central Register of Controlled Trials was performed (August 1, 2018) to detect all randomized controlled trials (RCTs) of adult ICU patients receiving dexmedetomidine. Articles were included if they assessed the influence of dexmedetomidine compared to a sedative agent on incidence of ICU delirium or treatment of this syndrome. Accordingly, relevant articles were allocated to the following two groups: (1) articles that assessed the delirium incidence (incidence comparison) or articles that assessed the treatment of delirium (treatment comparison). Incidence of delirium and delirium resolution were the primary outcomes. We combined treatment effects comparing dexmedetomidine versus (1) placebo, (2) standard sedatives, and (3) opioids in random-effects meta-analyses. Risk of bias for each included RCT was assessed following Cochrane standards.

RESULTS: The literature search resulted in 28 articles (25 articles/4975 patients for the incidence comparison and three articles/166 patients for the treatment comparison). In the incidence comparison, heterogeneity was present in different subgroups. Administration of dexmedetomidine was associated with significantly lower overall incidence of delirium when compared to placebo (RR 0.52; 95% CI 0.39-0.70; I2 = 37%), standard sedatives (RR 0.63; 95% CI 0.46-0.86; I2 = 69%), as well as to opioids (RR 0.61; 95% CI 0.44-0.83; I2 = 0%). Use of dexmedetomidine significantly increased the risks of bradycardia and hypotension. Limited data were available on circulatory insufficiency and mortality. In the treatment comparison, the comparison drugs in the three RCTs were placebo, midazolam, and haloperidol. The resolution of delirium was measured differently in each study. Two out of the three studies indicated clear favorable effects for dexmedetomidine (i.e., compared to placebo and midazolam). The study comparing dexmedetomidine with haloperidol was a pilot study (n = 20) with high variability in the results.

CONCLUSION: Findings suggest that dexmedetomidine reduces incidence and duration of ICU delirium. Furthermore, our systematic searches show that there is limited evidence if a delirium shall be treated with dexmedetomidine.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Flükiger J, Hollinger A, Speich B, et al. Dexmedetomidine in prevention and treatment of postoperative and intensive care unit delirium: a systematic review and meta-analysis. Ann Intensive Care. 2018. PMID: 30238227. doi:10.1186/s13613-018-0437-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。